Home › XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)
 

Keywords :   


XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)

2013-03-25 08:00:00| drugdiscoveryonline News Articles

Pfizer Inc. announced recently that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies

Tags: with japan treatment approved

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
More »